Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amodiaquine Hydrochloride

FDA-approved product (tablet, oral), marketed as Camoquin Hydrochloride.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Amodiaquine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Aminoquinolines
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BA06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis14.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 0 of 1 lab record
Open Amodiaquine Hydrochloride in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amodiaquine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Mali

    NCT03035305 · start 2016-08

    Registered record
    Registry ID
    NCT03035305
    Conditions
    Malaria
    Interventions
    Lipid-based Nutrient Supplement (LNS); Seasonal malaria chemoprevention
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-08
    Completion
    2016-11
    Enrolment
    36,717

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionLipid-based Nutrient Supplement (LNS); Seasonal malaria chemoprevention
    PhaseNot applicable
    Registry statusCompleted

  • Phase 2 Efficacy Study of Primaquine and Methylene Blue

    NCT02831023 · start 2016-07

    Registered record
    Registry ID
    NCT02831023
    Conditions
    Malaria
    Interventions
    Sulphadoxine-pyrimethamine; 0.25 mg/kg primaquine; Dihydroartemisinin-piperaquine; Methylene blue; Amodiaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-07
    Completion
    2017-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionSulphadoxine-pyrimethamine; 0.25 mg/kg primaquine; Dihydroartemisinin-piperaquine; Methylene blue +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)

    NCT02453308 · start 2015-08

    Registered record
    Registry ID
    NCT02453308
    Conditions
    Malaria, Falciparum
    Interventions
    ACT; TACT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2015-08
    Completion
    2018-03
    Enrolment
    1,110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum
    InterventionACT; TACT
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Optimization of Seasonal Malaria Chemoprevention (SMC) Delivery

    NCT02646410 · start 2014-08

    Registered record
    Registry ID
    NCT02646410
    Conditions
    Malaria; Anemia
    Interventions
    FPD+NDOT; FPD+DOT; DDD+NDOT; DDD+DOT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2014-08
    Completion
    2018-12
    Enrolment
    10,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Anemia
    InterventionFPD+NDOT; FPD+DOT; DDD+NDOT; DDD+DOT
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo

    NCT02741024 · start 2013-10

    Registered record
    Registry ID
    NCT02741024
    Conditions
    Malaria
    Interventions
    Amodiaquine-Artesunate (ASAQ); Artemether-Lumefantrine (AL)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-12
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionAmodiaquine-Artesunate (ASAQ); Artemether-Lumefantrine (AL)
    PhasePhase 4
    Registry statusCompleted

  • Adherence to Antimalarial Drugs in Sierra Leone

    NCT01967472 · start 2013-09-16

    Registered record
    Registry ID
    NCT01967472
    Conditions
    Malaria
    Interventions
    amodiaquine-artesunate (AQAS) fixed-dose; Artemether-lumefantrine combination (AL) dispersable
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-09-16
    Completion
    2014-01
    Enrolment
    1,145

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Interventionamodiaquine-artesunate (AQAS) fixed-dose; Artemether-lumefantrine combination (AL) dispersable
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger

    NCT01755559 · start 2013-06

    Registered record
    Registry ID
    NCT01755559
    Conditions
    Malaria
    Interventions
    Artesunate-amodiaquine; Dihydroartemisinin-piperaquine; Artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-06
    Completion
    2014-11
    Enrolment
    663

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionArtesunate-amodiaquine; Dihydroartemisinin-piperaquine; Artemether-lumefantrine
    PhasePhase 4
    Registry statusCompleted

  • Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria

    NCT01374581 · start 2012-05

    Registered record
    Registry ID
    NCT01374581
    Conditions
    Malaria
    Interventions
    Artemether/Lumefantrine; Artesunate/Amodiaquine; Quinine + Clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05
    Completion
    2014-06
    Enrolment
    2,117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionArtemether/Lumefantrine; Artesunate/Amodiaquine; Quinine + Clindamycin
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria

    NCT01378286 · start 2012-01

    Registered record
    Registry ID
    NCT01378286
    Conditions
    Malaria
    Interventions
    ARTESUNATE + AMODIAQUINE; Chloroquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-06
    Enrolment
    380

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionARTESUNATE + AMODIAQUINE; Chloroquine
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children

    NCT01407887 · start 2011-08

    Registered record
    Registry ID
    NCT01407887
    Conditions
    Uncomplicated Falciparum Malaria
    Interventions
    artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-08
    Completion
    2011-12
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Falciparum Malaria
    Interventionartesunate (AS) - amodiaquine (AQ) - methylene blue (MB)
    PhasePhase 2
    Registry statusCompleted

  • Trial of Malaria Seasonal IPTc Combined With Community Case Management

    NCT01449045 · start 2011-07

    Registered record
    Registry ID
    NCT01449045
    Conditions
    Malaria
    Interventions
    IPTc+CCM; Community Case Management with artemether-lumefantrine (AL)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-07
    Completion
    2012-02
    Enrolment
    4,554

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionIPTc+CCM; Community Case Management with artemether-lumefantrine (AL)
    PhasePhase 3
    Registry statusCompleted

  • Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon

    NCT01845701 · start 2010-03

    Registered record
    Registry ID
    NCT01845701
    Conditions
    Malaria
    Interventions
    Artesunate-Amodiaquine; Dihydroartemisinine-Piperaquine; Artemether-lumefantrine combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-03
    Completion
    2015-04
    Enrolment
    720

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionArtesunate-Amodiaquine; Dihydroartemisinine-Piperaquine; Artemether-lumefantrine combination
    PhasePhase 3
    Registry statusCompleted

  • Impact of Malaria Prevention on Health and Education in Kenyan Schoolchildren

    NCT00878007 · start 2010-01

    Registered record
    Registry ID
    NCT00878007
    Conditions
    Anaemia; Malaria
    Interventions
    Intermittent screening and treatment for malaria; Teacher training on literacy instruction; IST plus literacy instruction programme
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-01
    Completion
    2012-04
    Enrolment
    5,177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaemia; Malaria
    InterventionIntermittent screening and treatment for malaria; Teacher training on literacy instruction; IST plus literacy instruction programme
    PhaseNot applicable
    Registry statusCompleted

  • Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire

    NCT01023399 · start 2009-11

    Registered record
    Registry ID
    NCT01023399
    Conditions
    Malaria
    Interventions
    Artesunate + Amodiaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-11
    Completion
    2013-10
    Enrolment
    580

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionArtesunate + Amodiaquine
    PhasePhase 4
    Registry statusCompleted

  • In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso

    NCT00808951 · start 2008-12

    Registered record
    Registry ID
    NCT00808951
    Conditions
    Malaria
    Interventions
    Artesunate-amodiaquine; Artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-12
    Completion
    2011-02
    Enrolment
    440

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionArtesunate-amodiaquine; Artemether-lumefantrine
    PhasePhase 4
    Registry statusCompleted